Paper30510550
Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells.
Murad JP and 10 others. Front Immunol, 2018. Cited by 117 papers, by iCite.
Cite this record
ConductScience Library. Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. Papers, record 30510550. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30510550
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glycoproteins | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Ovarian Neoplasms | Major topic |
| Peritoneal Neoplasms | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| Xenograft Model Antitumor Assays | Major topic |
| Animals | |
| Antigens, Neoplasm | |
| Cell Line, Tumor | |
| Female | |
| Humans | |
| Kaplan-Meier Estimate | |
| Mice | |
| T-Lymphocytes | |
| Tumor Burden |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30 CA033572 | NCI NIH HHS | United States | P30CA033572 | PubMed and NIH |
Source NIH RePORTER
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28344808 | Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. | J Immunother Cancer | 2017 | https://conductscience.org/library/papers/28344808 | PubMed |
| 2 | 25949921 | IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. | Oncoimmunology | 2015 | https://conductscience.org/library/papers/25949921 | PubMed |
| 3 | 10499640 | Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. | Clin Cancer Res | 1999 | https://conductscience.org/library/papers/10499640 | PubMed |
| 4 | 3881173 | Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein. | Cancer Res | 1985 | https://conductscience.org/library/papers/3881173 | PubMed |
| 5 | 3396010 | Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. | Cancer Res | 1988 | https://conductscience.org/library/papers/3396010 | PubMed |
| 6 | 22330761 | Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. | J Transl Med | 2012 | https://conductscience.org/library/papers/22330761 | PubMed |
| 7 | 14654532 | In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants. | Clin Cancer Res | 2003 | https://conductscience.org/library/papers/14654532 | PubMed |
| 8 | 25939063 | 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. | Nat Med | 2015 | https://conductscience.org/library/papers/25939063 | PubMed |
| 9 | 29554494 | Driving CARs on the uneven road of antigen heterogeneity in solid tumors. | Curr Opin Immunol | 2018 | https://conductscience.org/library/papers/29554494 | PubMed |
| 10 | 28003642 | CAR T-cell therapy of solid tumors. | Immunol Cell Biol | 2017 | https://conductscience.org/library/papers/28003642 | PubMed |
| 11 | 18354214 | Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. | J Immunol | 2008 | https://conductscience.org/library/papers/18354214 | PubMed |
| 12 | 28029927 | Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. | N Engl J Med | 2016 | https://conductscience.org/library/papers/28029927 | PubMed |
| 13 | 29370379 | Glycan-directed CAR-T cells. | Glycobiology | 2018 | https://conductscience.org/library/papers/29370379 | PubMed |
| 14 | 23939024 | Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. | Mol Ther | 2013 | https://conductscience.org/library/papers/23939024 | PubMed |
| 15 | 22902507 | Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. | Cancer Lett | 2013 | https://conductscience.org/library/papers/22902507 | PubMed |
| 16 | 25366031 | Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. | Mol Ther | 2015 | https://conductscience.org/library/papers/25366031 | PubMed |
| 17 | 24970145 | Sialyl-tn in cancer: (how) did we miss the target? | Biomolecules | 2012 | https://conductscience.org/library/papers/24970145 | PubMed |
| 18 | 8575795 | Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. | Hybridoma | 1995 | https://conductscience.org/library/papers/8575795 | PubMed |
| 19 | 20628030 | Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. | Clin Cancer Res | 2010 | https://conductscience.org/library/papers/20628030 | PubMed |
| 20 | 26352543 | Smart CARs engineered for cancer immunotherapy. | Curr Opin Oncol | 2015 | https://conductscience.org/library/papers/26352543 | PubMed |
Cited by90
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 117 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42677388 | From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O-GalNAc Glycosylation in Cancer. | Chem Rev | 2026 | https://conductscience.org/library/papers/42677388 | PubMed |
| 42436932 | Focal radiotherapy improves CAR T cell therapy targeting prostate cancer. | bioRxiv | 2026 | https://conductscience.org/library/papers/42436932 | PubMed |
| 42340347 | Cancer-associated alterations in O-GalNAc glycosylation. | Glycobiology | 2026 | https://conductscience.org/library/papers/42340347 | PubMed |
| 42311665 | Systematic optimization of PD-L1 and CLDN18.2 CAR-T designs identifies a bicistronic dual-target, double-CD3ζ architecture with enhanced antitumor activity in gastric cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42311665 | PubMed |
| 42239424 | Spatial Regulation of CAR Signaling Enables Logic-Gated Activity. | bioRxiv | 2026 | https://conductscience.org/library/papers/42239424 | PubMed |
| 42039159 | CAR-T cell therapy for pancreatic cancer: Translating emerging targets and dual-targeting strategies from solid tumors. | Front Immunol | 2026 | https://conductscience.org/library/papers/42039159 | PubMed |
| 41807638 | Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics. | Nat Rev Clin Oncol | 2026 | https://conductscience.org/library/papers/41807638 | PubMed |
| 41646434 | Emerging immunotherapeutic strategies for malignant serous effusions: current evidence and future directions. | Front Oncol | 2026 | https://conductscience.org/library/papers/41646434 | PubMed |
| 41608579 | Imaging CRISPR-edited CAR-T cell therapies with optical and positron emission tomography reporters. | Theranostics | 2026 | https://conductscience.org/library/papers/41608579 | PubMed |
| 41590866 | Atrial Fibrillation Recurrence After Catheter Ablation Is Associated with TAG72 Protein. | J Cardiovasc Dev Dis | 2026 | https://conductscience.org/library/papers/41590866 | PubMed |
| 41455063 | Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer. | Stem Cell Rev Rep | 2026 | https://conductscience.org/library/papers/41455063 | PubMed |
| 41097743 | The Tumor Environment in Peritoneal Carcinomatosis and Malignant Pleural Effusions: Implications for Therapy. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41097743 | PubMed |
| 41094506 | Post-translational modifications in ovarian cancer: implications for immunotherapy: a mini-review. | J Ovarian Res | 2025 | https://conductscience.org/library/papers/41094506 | PubMed |
| 41034514 | Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. | Nat Biomed Eng | 2026 | https://conductscience.org/library/papers/41034514 | PubMed |
| 40981188 | Advances in Adoptive Cell Therapies in Cancer: From Mechanistic Breakthroughs to Clinical Frontiers and Overcoming Barriers. | Med Sci (Basel) | 2025 | https://conductscience.org/library/papers/40981188 | PubMed |
| 40958736 | Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers. | J Surg Oncol | 2025 | https://conductscience.org/library/papers/40958736 | PubMed |
| 40925376 | Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors. | Cell Rep Med | 2025 | https://conductscience.org/library/papers/40925376 | PubMed |
| 40861448 | Challenges in the preclinical design and assessment of CAR-T cells. | Front Immunol | 2025 | https://conductscience.org/library/papers/40861448 | PubMed |
| 40382583 | Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines. | Exp Hematol Oncol | 2025 | https://conductscience.org/library/papers/40382583 | PubMed |
| 40264184 | The potential of chimeric antigen receptor -T cell therapy for endocrine cancer. | World J Surg Oncol | 2025 | https://conductscience.org/library/papers/40264184 | PubMed |
Genes27
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30510550
GET https://conductscience.org/api/papers/v1/30510550/references?page=2